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Summary
There are limited recommendations for fasting in many chronic diseases such as 
adrenal insufficiency (AI). Research in such situations highlights potential for com-
plications and need for education for patients with AI undertaking fasting during 
Ramadan. This article aimed to provide up-to-date guidance for healthcare profes-
sionals to educate, discuss and manage patients with AI who are considering fast-
ing in Ramadan and is religiously compatible. Latest guidance on this topic and the 
evidence base for steroid dosing are reviewed and discussed. Risk stratification for 
patients with AI and optimal strategies for management, including steroid dosing, are 
detailed. Our review highlights that patients with AI wishing to fast should undergo 
a thorough risk assessment ideally several months before Ramadan. ‘High risk’ and 
‘Very high risk’ patients should be encouraged to explore alternative options to fast-
ing discussed below. Prior to the commencement of Ramadan, all patients must re-
ceive up-to-date education on sick day rules, instructions on when to terminate their 
fast or abstain from fasting, carry steroid warning information and must have a valid 
intramuscular (IM) hydrocortisone pack and know how to administer this. Switching 
patients with AI desiring to fast from multiple daily hydrocortisone replacement to 
prednisolone 5 mg once daily at dawn (during Suhoor or Sehri) is recommended and 
discussed. Patients on fludrocortisone for AI should be advised to take their total 
dose at dawn. We provide practically relevant case-based scenarios to help with the 
application of this guidance. Future efforts need to focus on healthcare professional 
awareness and further research in this setting.
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1  | INTRODUC TION
During the month of Ramadan, the majority of Muslims globally ob-
serve the religious obligation of fasting (abstaining from food and 
drink) from dawn till sunset for 29 or 30 consecutive days.1,2 As the 
timing of Ramadan is based on the lunar calendar, Ramadan falls 
11 days earlier annually and over a 33-year period, passes through 
all four seasons, with consequential shorter fasts in winter and lon-
ger fasts in the summer months.3 Fasts can therefore stretch to up 
to 20 hours in temperate regions, such as in the summer in parts of 
the UK. It is common practice to have one meal (known as Suhoor 
or Sehri) just before dawn and another (known as Iftar) after sun-
set. Taking medicines orally and intranasally is considered breaking 
a fast.4 Therefore, oral agents should be taken before dawn or after 
sunset if the patient wants to fast. Patients with AI who partake in 
fasting may, therefore, be at risk of dehydration and an adrenal crisis.
Adrenal cortisol secretion has a circadian rhythm with peak lev-
els at around dawn and levels that decline during the day with low 
levels at night (when asleep). AI can result from primary (adrenal dis-
ease including Addison’ disease), secondary (anterior pituitary dis-
ease) and tertiary (being on suppressive doses of exogenous steroids 
for another condition) causes. Depending on the type of AI, different 
approaches in management may be needed; however, all patients 
with AI need glucocorticoid replacement to try and mimic the nat-
ural circadian rhythm of cortisol secretion.5 Religious fasting could 
be at odds to the multiple daily dosing mandated with the standard 
treatment regimen associated with hydrocortisone replacement. 
Furthermore, changes in daily routine and behaviour, with some 
individuals staying up late into the night, may alter cortisol rhythm 
and therefore dosing and timing requirements during this month.6-8 
Predicting how to manage this group needs further research, as un-
necessary excessive steroid doses may be harmful and inadequate 
steroid cover may result in an adrenal crisis. Risks of adrenal crisis 
may be even higher in primary AI with mineralocorticoid deficiency, 
or secondary AI with concomitant pituitary (diabetes) insipidus as 
compared to other forms, due to the greater risk of electrolyte im-
balance and hypovolaemia.9,10
With up to 1.8 billion Muslims throughout the world and 3.4 mil-
lion Muslims in the UK, it is estimated that approximately 450 000-
750 000 people worldwide and 850-1450 people in the UK are likely 
to be considering fasting with AI during the month of Ramadan.11-15 
Given the rising incidence as well as other aetiologies for long-term 
steroid dependence, this figure is likely to be higher in the UK. 
Fasting with AI can result in complications, especially if the patient’s 
understanding of their health condition is low.16 Furthermore, there 
is evidence to suggest that many patients continue to fast despite 
complications occurring.16 Therefore, it is vital that people on glu-
cocorticoid replacement wishing to fast are educated on the nature 
of their condition as well as the requirements of fasting, to empower 
them to make an informed decision about fasting and how to mini-
mize the potential risks to themselves.
Patients on long-term glucocorticoid replacement wishing to 
fast need a thorough clinical assessment, ideally some months 
before Ramadan, which includes a review of their regular medica-
tions, complications, co-morbidities and social and lifestyle factors 
to help determine what is best for them. Guidance on safe fasting 
and education on sick day rules combined with instructions on when 
to urgently terminate their fast is essential. For example, patients 
who are unwell enough to contemplate sick day rules ought not to 
fast that day. Despite such advice, some patients may choose to fast 
against medical advice, and it is important then to try and ensure this 
happens safely.
Healthcare professionals (HCPs), in particular endocrinologists, 
can play a key role in optimizing patients with AI to fast and help 
them to make the correct decisions with regard to their health and 
fasting. At present, there is a brief consensus of South Asian guide-
line on this topic.10 However, given the emergence of recent evi-
dence and the longer duration of fasts in many temperate countries, 
further guidance is needed which this article intends to address.
2  | METHODS
This guideline aims to provide guidance for HCPs managing patients 
with AI who wish to partake in religious fasting. Given the paucity 
of formal guidance and consensus of professional opinion on this 
important topic, the Society for Endocrinology commissioned the 
authors to undertake a review of the evidence and provide expe-
rience-based guidance for HCPs in the UK and abroad. The authors 
used a combination of the limited published literature on fasting with 
AI, available research on fasting with other long-term conditions 
and clinical experience in this setting to help inform this guidance. 
Furthermore, existing experience with once-daily steroid options as 
an alternative to multiple hydrocortisone dosing in AI was reviewed.
Finally, the guidance and advice that is proposed by the authors 
in this review is for a nonpandemic or prevailing mitigating circum-
stances. Where appropriate, any additional or specific guidance, for 
example pertaining to COVID-19, has been clearly outlined.
2.1 | Section 1: Glucocorticoids for primary, 
secondary or tertiary adrenal failure and 
considerations for fasting
2.1.1 | Standard glucocorticoid 
replacement regimens
Patients may be on hydrocortisone, which owing to its short half-
life needs to be taken twice or thrice daily, prednisolone which has 
a longer half-life and can be taken once daily on waking, cortisone 
acetate which is taken twice daily or modified-release preparations 
of hydrocortisone which are typically taken once a day.17-19
Additionally, patients with secondary AI may be on other pi-
tuitary hormone replacement including thyroxine, growth hor-
mone, sex steroids (testosterone or oestrogen) and desmopressin, 
and those with primary AI may also be on fludrocortisone. Whilst 
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these hormone replacements have briefly been discussed, this ar-
ticle aims to focus on glucocorticoid replacement in patients with 
primary or secondary AI. It is crucial, however, that clinicians con-
sider the impact fasting may have on patients requiring multiple 
hormone replacements when advising them on how to take their 
medications during a fast and whether indeed it is safe for them 
to fast at all.
2.1.2 | Ramadan-specific steroid regimens for 
consideration
Although twice-daily hydrocortisone is a potential option, the doses 
will need to be administered at dawn and sunset. If the day is long, 
such as during the long summer days in the UK, cortisol levels are 
likely to fall significantly before sunset and so patients on this regi-
men need to be advised to terminate their fast if they become un-
well before sunset. A typical replacement dose is 15-25 mg taken at 
higher doses in the morning, noon and lower dose in early evening. 
There is no available evidence to suggest that the ‘stress’ of fast-
ing warrants a dose increment in steroids; however, this is some-
thing that should be individualized and could form part of future 
research. Furthermore, stress from partaking in activities such as 
optional evening prayers (called Tarawih) which last approximately 
1.5-2 hours may need additional consideration.
Once-daily prednisolone is an easier alternative and is used at 
doses of 3-5 mg in most patients outside fasting.17-19 There has been 
one randomized double-blinded controlled trial comparing pred-
nisolone 5 mg in the morning and placebo at sunset, to twice-daily 
hydrocortisone (10 mg + 5 mg) that showed no difference in any 
markers of well-being or risk of adrenal crisis.20
Another potential option are modified-release hydrocorti-
sone preparations.21 These are currently very rarely prescribed in 
the UK.22 Whilst patients taking modified-release hydrocortisone 
preparations can theoretically fast without any dose adjustments, 
their very high costs, poor availability worldwide and no reported 
experience in this setting do not make them a suitable option as a 
first-line recommendation for Ramadan-specific steroid dosing.
A single tablet of prednisolone 5 mg has the advantage of being 
widely available throughout the world and is the only glucocorticoid 
available in many countries. It may also offer a theoretical advan-
tage in temperate countries such as the UK, which are further from 
the equator and where the current duration of fasts is longer than 
in North Africa where this trial was undertaken.18 The option of 
lower doses such as 3 or 4 mg daily would be interesting to study 
in Ramadan, but 1 mg tablets of prednisolone are not widely avail-
able. The EU-AIR study highlighted that majority of patients are on 
hydrocortisone and some patients are over-replaced which may be 
responsible for the adverse cardiometabolic profile in these individ-
uals.23 Prednisolone has a longer half-life than hydrocortisone, so 
the dose equivalence is not linear. The dose equivalence ratio for 
hydrocortisone is between 6:1 and 8:1.24 A full replacement dose 
of prednisolone is between 2.5 and 5 mg once daily.17,19 Further 
randomized controlled trials to determine whether lower doses are 
sufficient are needed to determine optimum replacement strategies.
Mineralocorticoid replacement should be continued at the same 
dose. Fludrocortisone is usually taken as 50-100 μg once daily; how-
ever, doses may be higher in some individuals. Synthetic glucocorti-
coids such as prednisolone have lower mineralocorticoid activity as 
compared to hydrocortisone.25 Given their relatively modest contri-
butions towards mineralocorticoid replacement, hydrocortisone to 
prednisolone conversions do not usually need additional fludrocor-
tisone doses.
Most patients with primary AI should therefore take 5 mg 
prednisolone and their usual morning dose fludrocortisone at 
dawn (during Suhoor or Sehri) if they choose to partake in fasting. 
Conversion from hydrocortisone to prednisolone can occur immedi-
ately before the month of Ramadan starts.20
Patients with secondary AI should preferably have all their re-
placement hormones including the choice of steroid, thyroxine, 
growth hormone and sex steroids optimized prior to Ramadan. 
Patients who are on higher doses of steroids for other conditions 
should consult their specialists about whether fasting is safe and 
should continue their steroid treatment at the same dose if over an 
equivalent of prednisolone 5 mg.
Pregnant and breastfeeding women are discussed in more detail 
in the case-based scenario section of this review (Section 4). In rela-
tion to pregnancy, a low threshold to not fast should be advocated, 
particularly when there is clinical uncertainty in relation to outcomes 
or there is a genuine or legitimate fear of harm as outlined in the 
following section. However, if mothers were insistent on fasting, es-
sentially these women could also be managed with once-daily pred-
nisolone (3-5 mg depending upon the stage of pregnancy). During 
lactation, this results in negligible amounts of prednisolone in breast 
milk and is unlikely to cause any systemic effects in the infant.26
2.2 | Section 2: Health considerations relating to 
fasting in Ramadan and adrenal insufficiency
2.2.1 | General principles and considerations
At its core, Islamic law, the Shari'ah, aims to protect integral val-
ues including an individual’s life, well-being and health.27 A degree 
of difficulty as a means of encouraging virtues such as patience is 
expected in Ramadan for those partaking in it; however, religious 
law encourages the pre-emption of potential harm to health and 
well-being and provides exemptions and alternatives in place of the 
usual rituals.28 Islamic rulings make several exceptions to lift the ob-
ligation of fasting for those in whom it may entail hardship such as 
the elderly, those who are travelling, those with significant mental 
health illness and pregnant women (if there is known, or potential 
risk, or an appropriate HCP has legitimate concern to the health of 
the mother and/or foetus).29,30 At present, there is some evidence 
that fasting during pregnancy may have negative effects on the un-
born foetus.31-33
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2.2.2 | Terminating a fast and use of medication 
when fasting
Islam supports those with appropriate ailments to terminate the fast 
or be exempted from fasting if there is reasonable expectation that a 
person will become ill (eg those with pre-existing or current physical 
illness which may be significantly exacerbated by fasting are permit-
ted to not fast), or that their health would be compromised such that 
they would not be able to function in a safe or responsible manner 
due to physiological compromise.34 In such a circumstance, the two 
main alternative options to fasting are as follows1,3:
• Making up the missed fast when their health permits them to do 
so—either when the illness is no longer present, such as in acute 
illness, or when the illness is not worsened by fasting at another 
point in time in relation to chronic illness, for example fasting in 
the winter when the days are shorter.
• An exemption from fasting in those whose illness will not permit 
them to keep fasts indefinitely, this being replaced by a require-
ment to feed the poor (fidyah).
Reasonable expectation of illness or compromise would be de-
termined by applying one of the three following criteria: (a) prior ex-
perience of what fasting does to the ailment; (b) common knowledge 
(eg effect on a person with Addison’s disease who does not take 
their latter doses of hydrocortisone tablets); and (c) the opinion of a 
qualified physician on the matter.29 Appropriate ailments can also in-
clude old age, or a condition which is stable, but through fasting the 
condition can adversely affect health or increase the risk of doing 
so especially with abstaining from use of medications, for example 
steroid replacement in adrenal failure. A more detailed exposition 
pertaining to the religious obligation of fasting and considerations 
in relation to health and illness has been published elsewhere by au-
thors of this review.35
It should be highlighted that although unanimous opinion exists 
on certain issues, there is a breadth of opinion on a variety of is-
sues and healthcare providers may encounter Muslims with differ-
ing viewpoints on these issues. Furthermore, a significant number 
of people who have been advised not to fast by their HCP may still 
choose to do so.16,36
2.3 | Section 3: Practical guidance for healthcare 
practitioners when approaching this situation in clinic
Whilst all patients with AI have a higher probability of complica-
tions during prolonged fasting than the general population, it may 
be useful for clinicians to risk stratify patients when discussing the 
implications of fasting on their patient’s health. This risk stratifica-
tion should take into consideration not only the patient’s endocrine 
condition but also their other co-morbidities, medications and over-
all frailty. Patients, as well as clinicians, may find this approach ben-
eficial when making informed decisions about partaking in fasting 
during Ramadan. Such an example of risk stratification has been uti-
lized in authoritative international diabetes guidance (International 
Diabetes Federation endorsed Diabetes and Ramadan [DAR] 
Guidelines) and has been approved by the Islamic Organization for 
Medical Sciences and the International Islamic Fiqh Academy.1
Thus, the authors propose the following categorization for risk 
stratification as outlined in Table 1, using the same type of cate-
gorization and definitions applied by DAR. Patients in the ‘low and 
moderate’ risk category could be supported through religious fasting 
with appropriate education and counselling whilst those in the ‘high’ 
risk and ‘very high’ risk category should be encouraged and sup-
ported to explore alternative options to fasting. However, this list is 
not exhaustive and should assist and does not replace the clinician’s 
overall judgement. Each patient’s scenario should be assessed based 
on their own individual clinical and social circumstances; however, 
the list in Table 1 provides a general guide.
In the context of prevailing mitigating circumstances, for ex-
ample the current COVID-19 global pandemic, the authors advise 
upgrading the patient’s baseline categorization to the next categori-
zation, for example moderate risk becoming high risk. Further details 
are available in resources developed specifically for this setting.37 
Such a recommendation is based on current expert advice given in 
relation to patients with adrenal insufficiency (AI) being at increased 
TA B L E  1   Risk stratification for fasting with adrenal insufficiency
Low/Moderate risk
(Decision to not fast based on discretion of medical opinion and ability 
of the individual to tolerate fast)
Stable and well-controlled adrenal insufficiency (low)
No significant co-morbidities (low)
Treated concomitant mineralocorticoid deficiency (moderate)
High risk
(Advice should NOT fast)
Recent diagnosis of steroid dependence within the last 3 mo
Pregnancy
Very high risk
(Advice MUST NOT fast)
Multi-morbidity: major organ system involvement
Concomitant diabetes mellitus on insulin treatment
Concomitant pituitary (diabetes) insipidus
Adrenal crises in the last 12 mo
Untreated concomitant mineralocorticoid deficiency
Untreated TSH deficiency
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risk of severe illness from COVID-19.38,39 Given the significant bur-
den on healthcare services from the current COVID-19 pandemic, 
the recommendation also attempts to minimize the strain on health 
services given possible requirements for access to HCPs for edu-
cation or prescription changes. However, the authors acknowledge 
that such prevailing circumstances are evolving, and the latest advice 
and evidence can also change. Therefore, HCPs are advised to check 
appropriate national specialist bodies websites for latest guidance.
2.3.1 | General education and emergency 
management plans
• All patients with AI wishing to fast should receive up-to-date edu-
cation on steroid sick day rules (verbal and written) and must have 
a valid intramuscular (IM) hydrocortisone pack with training on 
how to administer this prior to the commencement of Ramadan.
• Patients should be warned of the symptoms of acute AI and 
should be advised to urgently terminate the fast and administer 
IM hydrocortisone if they develop these symptoms.
• All patients should always also be given and advised to carry a 
steroid warning card with details of their local endocrine unit.40
• In addition, patients with concurrent mineralocorticoid deficiency 
should be advised to avoid prolonged sun exposure to minimize 
salt and water losses.
• Adrenal crisis needs to be managed urgently in hospital, with in-
travenous fluids. Patients should not delay hospital admission for 
fear of contracting COVID-19.
Figure 1 is a flow diagram which HCPs are encouraged to follow 
when discussing fasting in patients with AI (modified from Ref. 35), 
and Table 2 provides a summary. Table 3 provides sick day rules guid-
ance for Ramadan and covers guidance during intercurrent illness, in 
line with previous guidance.41 Any situation that requires doubling 
of glucocorticoid doses or emergency hydrocortisone injections 
warrants immediate breaking of the fast and abstinence from fasting 
until complete recovery.
2.3.2 | Hydration advice
It is extremely important that all patients ensure adequate hydra-
tion with noncaffeine containing fluids between dusk (Iftar) and 
dawn (Suhoor or Sehri). Given the presence of concomitant min-
eralocorticoid deficiency, patients with primary AI may be at in-
creased risk of hypovolaemia and dehydration especially if their 
condition has not been adequately treated.9,10 As a general precau-
tion, patients with primary AI may be advised to rehydrate with 
electrolyte replacement (fluids with added salt) whilst those with 
secondary AI with pituitary (diabetes) insipidus are likely to require 
more free water.
2.3.3 | Patients on exogenous glucocorticoids for 
other conditions
Patients on oral steroids for other conditions should consult their 
specialists regarding safety of fasting. In most scenarios, where 
someone is well enough to undertake fasting and is on exogenous 
glucocorticoids, long-acting formulations, such as prednisolone, are 
typically used. For patients who are on a tapering dose of predniso-
lone for other conditions, with no underlying AI, there is no evidence 
that a change in dose is required during fasting. These should be 
continued during fasting at the same dose. Further dose reductions 
should be discussed with their physicians and may be delayed until 
Ramadan is over.
F I G U R E  1   Flow diagram for healthcare 
professionals to help with decision-
making, discussions and management of 
patients with adrenal insufficiency (AI) 
who are intending to fast [Colour figure 
can be viewed at wileyonlinelibrary.com]
Paent intends to fast Connue current treatment
No
Explore paent wishes 
for Ramadan including 
spiritual, lifestyle, 
work and social
Risk strafy paent
Yes
Very high Risk
High Risk
‘Low - Moderate’ Risk
Explore alternave 
opons:
- Non-consecuve 
fasts
- Fasng on shorter 
days (e.g. winter)
- Fidyah
Paent sll 
chooses to fast
Educaon, opmisaon & emergency 
plans:
- Educate paent on risks and reinforce sick day 
rules
- Opmise steroid replacement
- Provide valid steroid injecon pack and steroid 
warning card with contacts of local endocrine 
team
- Advise to terminate fast and administer 
emergency steroid injecon if unwell or 
developing symptoms of adrenal insufficiency
- Consider trial fasts (e.g. 1 month before Ramadan)
Yes
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2.4 | Section 4: Examples of case-based scenarios 
with potential treatment options discussed for 
patients with adrenal insufficiency intending to fast
The following scenarios cover a range of likely cases HCPs are likely 
to encounter in relation to patients with AI and intending to fast and 
possible options that can be offered to facilitate safe fasting. These 
scenarios assume the absence of prevailing mitigating circumstances 
(at the time of publication, such as the COVID-19 global pandemic). 
It must be made clear from the outset that regardless of any ad-
vice offered by the HCP, the final decision to fast or otherwise rests 
with the patient and clear documentation of relevant discussions 
and outcomes should be documented or mentioned in relevant clini-
cal letters. Further in any of the following scenarios or the like, if 
it becomes apparent that patients are struggling to fast (including 
having to prematurely terminate the fast) or health or safety con-
cerns emerge by ongoing fasting, then terminating the fast and not 
fasting the rest of the month of Ramadan is the default clinical and 
religious standpoint.1,30,35
2.4.1 | Scenario 1—Fasting with ACTH deficiency
Mrs A is a 45-year-old lady with partial ACTH deficiency following 
transsphenoidal surgery and external beam radiotherapy for acro-
megaly. She takes hydrocortisone once a day on waking and has 
done so for many years. She is well-versed with sick day rules. Both 
she and her husband are trained in administering IM hydrocortisone. 
She would like to fast during Ramadan and has in fact been doing 
this for the last few years but has never discussed this before. She 
reports taking hydrocortisone at Suhoor (dawn). She is able to fast 
TA B L E  2   Summary of guidance for the management of patients 
with adrenal insufficiency who wish to fast during the month of 
Ramadan
Patients on long-term glucocorticoid replacement wishing to fast 
should undergo a thorough risk assessment ideally several months 
before Ramadan
‘High risk’ and ‘Very high risk’ patients should be encouraged to 
explore alternative options to fasting, which may require input 
from family members and/or the appropriate religious authority
All patients must receive up-to-date education on sick day rules 
combined with instructions on when to terminate their fast or 
abstain from fasting
The above point is of particular importance in the context of any 
prevailing unique and mitigating circumstances, for example the 
COVID-19 pandemic
Patients must have a valid intramuscular (IM) hydrocortisone pack 
and know how to administer this prior to the commencement of 
Ramadan
All patients should be advised to carry a steroid warning card with 
contact details of their next of kin and local endocrine unit at all 
times
Patients who use their IM hydrocortisone and are still unwell should 
go directly to hospital for intravenous fluids, which are lifesaving 
especially with the COVID-19 pandemic
Switching patients with adrenal insufficiency (AI) who are 
wishing to fast from multiple daily hydrocortisone replacement 
to once-daily prednisolone at dawn (during Suhoor or Sehri) is 
recommended. In most cases, such as patients who are on a total 
daily hydrocortisone dose between 15 and 30 mg daily, a dose of 
prednisone 5 mg once daily will be sufficient
Patients on fludrocortisone for AI should be advised to take their 
total dose at dawn (during Suhoor or Sehri) and avoid prolonged 
sun exposure
Patients on steroids for other conditions with no concerns regarding 
adrenal insufficiency should consult their specialists about 
whether fasting is safe and should continue their steroid treatment 
at the same dose
Pregnant and breastfeeding patients with AI should be advised 
against fasting. This should be more strongly stated if there are 
concerns around absorption of steroids or other complications 
during pregnancy and in the post-partum period
TA B L E  3   Sick day rules for Adrenal Insufficiency in Ramadan
Type of illness Actions
Mild intercurrent illness 1. No further actions needed, however, 
if symptoms worsen, have a very low 
threshold to undertake actions listed 
below and maintain good hydration 
between Iftar and Sehri/Suhoor
Moderate intercurrent 
illness
1. Break your fast immediately and 
abstain from fasting
2. Double your usually daily 
glucocorticoid dose (eg if you are 
on prednisolone 5 mg once–daily, 
increase this to 10 mg once daily)
3. Rehydrate by drinking plenty of 
fluids
4. Always carry your steroid warning 
card with contact details of your local 
endocrine team
5. Ensure you have a valid steroid 
injection pack and that you or your 
carer or cohabitants are aware on how 
to administer this
6. Resume fasting only when you are 
completely well—if you are unsure, 
then seek medical advice before 
resuming your fasts
Severe intercurrent 
illness or persistent 
vomiting
1. Break your fast immediately and 
abstain from fasting
2. Give an emergency hydrocortisone 
IM injection (100 mg)
3. Seek urgent medical attention 
immediately as emergency 
management in hospital with 
intravenous fluids and hydrocortisone 
infusion is very likely to be needed
4. Resume fasting only when you are 
completely well—if you are unsure, 
then seek medical advice before 
resuming your fasts
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but finds herself feeling very low in energy by Iftar (sunset) time. She 
has struggled to take part in evening prayers (tarawih) after breaking 
her fast.
Discussion
Mrs A is in the low-risk category and has a good understanding of 
her condition. As she is receiving once-daily hydrocortisone, she 
could continue to take this during Ramadan prior to commencing 
her fast at Suhoor. However, an additional evening dose of hydro-
cortisone (eg 5 mg) can be considered particularly if she wishes to 
partake in evening prayers. Alternatively, temporarily switching to 
prednisolone 5 mg at dawn should be considered.
2.4.2 | Scenario 2—Fasting with primary adrenal 
insufficiency
Mr M is a 60-year-old gentleman with a long history of primary AI 
due to Addison’s disease for which he takes hydrocortisone (10 mg 
on waking, 10 mg at midday and 5 mg at 5 pm) and fludrocortisone 
(100 μg on waking and 50 μg in the evening). Although he has been 
discouraged from fasting in the past, he would like to attempt fasting 
during Ramadan this year and would like to discuss this.
Discussion
Given Mr M has primary AI, the risk of an acute adrenal crisis should 
be discussed. Patients with primary AI are likely to be at higher risk 
of adrenal crisis, than patients with secondary or tertiary AI, due 
to higher risks of dehydration and hypovolaemia from concomitant 
mineralocorticoid deficiency.9 Alternatives to fasting during the 
summer months should be discussed (as detailed in Section 2). If the 
patient still chooses to fast during Ramadan, nonconsecutive fasts 
and trial fasts should be encouraged.
To support fasting, hydrocortisone should be switched to once-
daily steroid replacement (eg prednisolone 5 mg at Suhoor) and he 
should be advised to take all of his fludrocortisone at this time as 
fludrocortisone has a long half-life, and splitting the dose has no 
advantage. Although not necessary, if the HCP or patient have un-
familiarity or uncertainty with this regimen, a trial on this new ste-
roid regimen of prednisolone 5 mg and fludrocortisone 150 μg every 
morning combined with an assessment of Mr M’s BP and electrolytes 
prior to the start of Ramadan is encouraged where possible. Steroid 
education and emergency management, as outlined in Section 3 
above, should be reinforced. Importance of hydration should be rein-
forced and considering fluids with electrolyte replacement (or added 
salt) should be considered.
2.4.3 | Scenario 3—Fasting with multi-morbidity and 
adrenal insufficiency
Mrs Y is a 75-year-old lady with congestive cardiac failure requir-
ing daily diuretics, type 2 diabetes mellitus on multiple daily insulin 
injections and secondary adrenal deficiency on replacement doses 
of hydrocortisone. She is aware of the risk of life-threatening adre-
nal crises, fluid overload and electrolyte disturbances through de-
laying and/or omitting her medications to partake in fasting during 
Ramadan. As her clinician, she would like to discuss whether fasting 
would be exempt given her multi-morbidities with you.
Discussion
Mrs Y is in the high-risk category and should be actively discouraged 
from fasting given the potential adverse effects on her health. She 
should be advised not to observe longer fasts, and even shorter fasts 
(eg in the winter months) as it is likely to cause harm to her health. 
Thus, as a perpetual circumstance to debarring safe fasting exists, 
Mrs Y would be advised to pay fidyah to the poor as an alternative. 
Where possible, input from other family members or the local imam 
should be considered.
2.4.4 | Scenario 4—Fasting with panhypopituitarism 
(secondary AI)
Miss Z is a 26-year-old lady with ACTH, TSH and gonadotrophin de-
ficiency. She is currently well managed on hydrocortisone (10 mg on 
waking, 5 mg at midday and 5 mg at 5 pm), levothyroxine (75 μg once 
daily) and sequential combined transdermal HRT. She would like to 
resume fasting which she undertook prior to her diagnosis 2 years 
ago.
Discussion
Given that Miss Z is well managed, she is low risk. For steroid re-
placement, as outlined previously, education, optimization and 
emergency plans should be discussed. As in case 2, once-daily ster-
oid dosing with prednisolone should be considered to give adequate 
steroid coverage through the day.
Fasting with well-controlled hypothyroidism is safe. Although 
levothyroxine can be taken at any time where it is permissible to 
eat and drink, it may be difficult to adhere to taking this as per 
usual recommendations (30 minutes before food to maximize its 
absorption) given the short window to eat and drink during the 
long summer fasts in Ramadan. Therefore, it is possible that during 
the month of Ramadan the absorption of levothyroxine may be re-
duced. This is unlikely to have a significant impact in most situa-
tions; however, depending on the patient’s practices, best options 
to time the intake of levothyroxine can be discussed. In most cases, 
this is immediately on waking for Suhoor or immediately after 
breaking fast at Iftar.
Transdermal medications are permitted during fasting.4 However, 
if the patient wishes to consider oral options which they can take 
when it is permissible to eat and drink, a switch can be considered 
ideally at least a month before Ramadan.
Whilst undergoing menstruation (naturally, or iatrogenically in-
duced), patients are exempt from fasting. However, they will have to 
make up for their missed fasts at a later date. However, as menstrual 
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bleeds in this situation are iatrogenically induced, patients, if they 
desire to, could be managed with a continuous combined HRT op-
tion, or continue back-to-back COCP usage if they would prefer to 
avoid menstrual bleeds during the month of Ramadan and revert to 
sequential combined options thereafter.
2.4.5 | Scenario 5—Fasting with panhypopituitarism 
(secondary AI) including pituitary (diabetes) insipidus
Mr X is a 54-year-old gentleman with panhypopituitarism secondary 
to a pituitary adenoma managed with 10 mg of hydrocortisone on 
waking and 5 mg at lunchtime, Nebido 1 g every 4 months, levothy-
roxine 100 μg and desmopressin 10 μg nasally twice daily.
He expresses a desire to fast during the month of Ramadan. He 
asks you about the practicalities of doing this.
Discussion
Given Mr X has pituitary (diabetes) insipidus along with cortisol, 
thyroid and gonadotrophin deficiency, he is in the high-risk cate-
gory and the clinician should explain the risks of severe dehydra-
tion, electrolyte imbalance along with risks of adrenal crisis to the 
patient. The patient’s anterior hormone deficiencies can be man-
aged as discussed in previous cases. However, given the prolonged 
fasts and disruption in regulating fluid and electrolyte homeosta-
sis in pituitary (diabetes) insipidus, there are no safe management 
strategies that can be considered. Thus, fasting should be strongly 
discouraged on health grounds. Furthermore, the intake of desmo-
pressin (oral or intranasal) is not permissible during a fast.4 Even 
nonconsecutive fasting or winter fasts would be risky in this situa-
tion. The HCP should discuss alternatives to fasting such as fidyah. 
To help aid discussions, input from other family members or the 
local imam can be considered.
In patients with mild pituitary (diabetes) insipidus on once-
daily desmopressin (morning or evening) who insist on partaking 
in Ramadan despite HCP recommendations and high risks of dehy-
dration, clinicians could consider supporting the patient if the fasts 
are <12 hours in duration and during the winter months; however, 
all other options of not partaking in fasts should be considered 
first. If faced with this situation, we would strongly encourage that 
the patient first undergoes a supervised trial fast with close fluid 
balance and electrolyte monitoring, prior to the commencement 
of Ramadan. That said, it is likely that most hospitals would not 
be able to support this, in which case fasting would not be rec-
ommended. If the patient still chooses to proceed with fasting, 
then they should be counselled on the potential risks, including 
very high risks of dehydration and hypernatraemia, particularly if 
they wish to partake in consecutive fasts during the summer days. 
Ensuring good hydration with water, rather than electrolyte-rich 
fluids, should be encouraged. They should be strongly advised to 
have a low threshold to terminate the fast and encouraged to hy-
drate themselves well.
2.4.6 | Scenario 6—Pregnant mothers and 
considerations for breastfeeding
Mrs B is a 28-year-old lady with adrenal suppression due to long-
term steroids for inflammatory bowel disease (IBD). Her IBD is now 
in remission; however, her adrenal axis did not fully recover and as a 
result she was commenced on hydrocortisone 10 mg on waking and 
5 mg in the early afternoon by her endocrinologist. She appropri-
ately increased the dose of hydrocortisone at the start of the third 
trimester to 15 mg on waking and 10 mg in the early afternoon. She 
is 24-week pregnant, and her obstetrician is happy with both her and 
her baby's progress.
She would like to fast during Ramadan which falls in her final 
trimester and early post-partum phase. She would like to discuss the 
safety of this with you.
Discussion
Pregnant patients are best advised to defer their fasts and make up 
for them after pregnancy if there are concerns of risk to the mother 
and/or foetus, as outlined earlier, by the pre-empting criteria to 
avoid fasting in mitigating circumstances.29 However, despite this, 
if a pregnant mother is considering fasting, important and relevant 
risks of causing harm to the mother and/or foetus should be commu-
nicated clearly, particularly where medical or scientific evidence is 
available. In this scenario, there are no specific additional risks from 
AI. Concomitant type 1 diabetes mellitus which can coexist with 
Addison’s disease would be an example of where a pregnant mother 
would be told unequivocally not to fast.30 This patient and others 
choosing to fast in the long summer period during pregnancy despite 
medical recommendations can be supported with standard preg-
nancy advice for AI, which for prednisolone treatment is 5 mg daily.
In the nonfasting individual, the dose of steroid replacement is 
unchanged in the first and second trimesters and is increased by 
20% to 40% in the third trimester. In the first trimester, predniso-
lone 3-5 mg once daily or hydrocortisone 20 mg divided into three 
doses is commonly used. Both are inactivated by 11-betaHSD type 
2 in the placenta (to prednisone and cortisone, respectively), so 
that neither has any effect on the foetus. Fluorinated steroids 
(such as dexamethasone) are not inactivated by 11-betaHSD type 
2 and also do not have mineralocorticoid activity.25 They should 
not be used as steroid replacement during pregnancy, but of 
course can be used where the aim is to treat the foetus, as with 
lung maturation.
Outside pregnancy, the evidence is that 3-4 mg daily is optimum, 
so the dose of 5 mg in the third trimester would be appropriate. The 
only evidence on dosing available at present suggests that 5 mg daily 
is safe and effective during Ramadan, although lower doses may be 
appropriate, further studies need to be undertaken to confirm this.20 
Patients must be advised to have a very low threshold to terminate 
fasting if they are unwell. Pregnant patients with AI should be ad-
vised against fasting if there are concerns around poor absorption of 
steroids, nausea, vomiting, hyperemesis, other complications during 
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pregnancy or intermediate or high risk of fasting with AI (Table 1). 
In this situation, the patient can make up for their fasts missed after 
pregnancy if deemed safe.
Similarly, during breastfeeding, patients may choose to defer 
their fasts and make up for them after breastfeeding, particularly if 
there is concern regarding milk production diminishing or the mother 
is unable to meet the necessary calorific demand in the short period 
available to eat between fasts. However, if they consider fasting and 
are low or intermediate risk, they can be supported with predniso-
lone 5 mg once daily. This results in negligible amounts of prednis-
olone in breast milk and is unlikely to cause any systemic effects in 
the infant.26
3  | CONCLUSION
This review presents a summary of research, guidance and consen-
sus of professional opinion from authors on the practical manage-
ment of AI in Ramadan. It highlights the importance of education 
and optimization of steroid replacement in this setting. As outlined 
in Ramadan guidance in relation to diabetes, there is a strong need 
for patient and HCPs and religious/community figureheads such 
as imams to engage with each other and discuss these contempo-
rary medical issues.30,35 Finally, future research work to explore 
unanswered questions and expand on the limited evidence base is 
needed.
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